Jian Lin

US Patent:

7217794, May 15, 2007

Filed:

Apr 2, 2004

Appl. No.:

10/817248

Inventors:

Sherin S. Abdel-Meguid - Exton PA, US
Robert E. Babine - Franklin MA, US
Hongfeng Deng - Acton MA, US
Lei Jin - Wellesley MA, US
Jian Lin - Walpole MA, US
Scott R. Magee - Somerville MA, US
Harold V. Meyers - Weston MA, US
Pramod Pandey - Canton MA, US
Michael J. Rynkiewicz - Boston MA, US
David T. Weaver - Newton MA, US
Zihong Gho - Southbury CT, US
Thomas D. Bannister - Northborough MA, US

Assignee:

Daiamed, Inc. - Cambridge MA

International Classification:

C07K 14/745
C07K 1/00
C07K 14/00

US Classification:

530384, 530350, 530380, 530381, 530412

Abstract:

The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.

US Patent:

7411719, Aug 12, 2008

Filed:

Jun 21, 2005

Appl. No.:

11/160364

Inventors:

David Miller - Wakefield MA, US
Barrett Comiskey - Shanghai, CN
Joseph M. Jacobson - Newton Centre MA, US
Bin Wu - Sharon MA, US
Charles Howie Honeyman - Roslindale MA, US
Jian Lin - Acton MA, US

Assignee:

E Ink Corporation - Cambridge MA

International Classification:

G02B 26/00
G09G 3/34
G03G 13/04

US Classification:

359296, 345107, 430 32

Abstract:

A two-phase electrophoretic medium comprises a continuous phase and a discontinuous phase. The discontinuous phase comprises a plurality of droplets, each of which comprises a suspending fluid and at least one particle disposed within the suspending fluid and capable of moving through the fluid upon application of an electric field to the electrophoretic medium. The continuous phase surrounds and encapsulates the discontinuous phase. To reduce the humidity sensitivity of the medium, a non-ionizable or crystalline polymer may be used as the continuous phase.

US Patent:

7501404, Mar 10, 2009

Filed:

Apr 4, 2006

Appl. No.:

11/398438

Inventors:

Thomas Bannister - Palm Beach Gardens FL, US
Cassandra Celatka - Hull MA, US
Nizal S. Chandrakumar - North Grafton MA, US
Hongfeng Deng - Acton MA, US
Zihong Guo - Southbury CT, US
Lei Jin - Wellesley MA, US
Tsvetelina Lazarova - Brookline MA, US
Jian Lin - Walpole MA, US
Scott T. Moe - Marlborough MA, US
Pamela Nagafuji - Cambridge MA, US
Manuel Navia - Lexington MA, US
Amy Ripka - Winthrop MA, US
Michael J. Rynkiewicz - Boston MA, US
Kerry L. Spear - Concord MA, US
James E. Stickler - Milton MA, US
Roger Xie - Southborough MA, US

Assignee:

DAIMED - Cambridge MA

International Classification:

C07D 205/08
C07D 205/085
C07D 401/14
C07D 401/12
C07D 401/06
C07D 403/12
C07D 403/14
C07D 403/04
A61K 31/397
A61K 31/506
A61K 31/4427
A61K 31/41

US Classification:

51421002, 51421005, 540200, 540354, 540355, 540360, 540362, 540363, 540364

Abstract:

Compounds are provided which have the structure.

US Patent:

7790707, Sep 7, 2010

Filed:

Mar 21, 2007

Appl. No.:

11/726356

Inventors:

Ashis Saha - Stow MA, US
Xiang Yu - Acton MA, US
Mercedes Lobera - Bolton MA, US
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Oren Becker - Mevaseret Zion, IL
Yael Marantz - Kadima, IL
Nili Schutz - Tel-Aviv, IL

Assignee:

EPIX Pharmaceuticals Inc. - Lexington MA

International Classification:

A61K 31/397
A61K 31/4166
C07D 205/04
C07D 403/02
C07D 403/06

US Classification:

51421001, 51421017, 51421018, 5142102, 514392, 5483147, 5483164, 5483255, 548950, 548953

Abstract:

The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.

US Patent:

7848007, Dec 7, 2010

Filed:

Jul 3, 2008

Appl. No.:

12/167290

Inventors:

David D. Miller - Wakefield MA, US
Barrett Comiskey - Shanghai, CN
Joseph M. Jacobson - Newton Centre MA, US
Bin Wu - Sharon MA, US
Charles Howie Honeyman - Roslindale MA, US
Jian Lin - Acton MA, US

Assignee:

E Ink Corporation - Cambridge MA

International Classification:

G02B 26/00
G03G 17/04

US Classification:

359296, 430 32

Abstract:

A two-phase electrophoretic medium comprises a continuous phase and a discontinuous phase. The discontinuous phase comprises a plurality of droplets, each of which comprises a suspending fluid and at least one particle disposed within the suspending fluid and capable of moving through the fluid upon application of an electric field to the electrophoretic medium. The continuous phase surrounds and encapsulates the discontinuous phase. To reduce the humidity sensitivity of the medium, a non-ionizable or crystalline polymer may be used as the continuous phase.

US Patent:

7855193, Dec 21, 2010

Filed:

Jul 24, 2006

Appl. No.:

11/491766

Inventors:

Ashis K. Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Concord MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Bedford MA, US
Robert Christian Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL

Assignee:

EPIX Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/397
A61K 31/5377
A61K 31/4525
A61K 31/4025
A61K 31/343
C07D 411/06
C07D 405/06
C07D 205/04
C07D 307/80

US Classification:

51421019, 5142335, 514320, 514422, 514469, 544153, 546196, 548517, 548953, 549467

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e. g. , for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

US Patent:

7919519, Apr 5, 2011

Filed:

Mar 21, 2007

Appl. No.:

11/726351

Inventors:

Roland Burli - Pasadena CA, US
Victor J. Cee - Thousand Oaks CA, US
Jennifer Golden - Simi Valley CA, US
Brian Alan Lanman - Oak Park CA, US
Susana Neira - Thousand Oaks CA, US
Ashis Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Bolton MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Washington DC, US
Robert C. Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL
Zhaoda Zhang - Andover MA, US

Assignee:

Epix Pharmaceuticals Inc. - Lexington MA

International Classification:

A61K 31/404
A61K 31/381
A61K 31/343
C07D 209/12
C07D 333/56
C07D 307/80

US Classification:

514419, 514443, 514469, 548494, 549 58, 549469

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e. g. , for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

US Patent:

8569282, Oct 29, 2013

Filed:

Dec 11, 2008

Appl. No.:

12/747109

Inventors:

Efrat Ben-Zeev - K. Motzkin, IL
Dongli Chen - Brighton MA, US
Merav Fichman - Modi'in, IL
Shomir Ghosh - Brookline MA, US
Steffi Koerner - Medford MA, US
Jian Lin - Acton MA, US
Yael Marantz - Kadima, IL
Rosa E. Melendez - Toronto, CA
Pradyumna Mohanty - Woburn MA, US
Sharon Shacham - Chestnut Hill MA, US
Zhaoda Zhang - Andover MA, US

Assignee:

CytoPathfinder, Inc. - Tokyo

International Classification:

C07D 471/04
A61K 31/4375

US Classification:

51421018, 514312, 514320, 5142305, 514309, 514403, 514375, 514321, 5142531, 544105, 544364, 546157, 546196, 546141, 5483625, 548221

Abstract:

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.